Beijing Luzhu Biotechnology (2480) Stock Overview

Beijing Luzhu Biotechnology Co., Ltd., a biotechnology company, focuses on the research and development, production, and sale of human vaccines and therapeutic biologics to prevent and control infectious diseases, and treat cancer and autoimmune diseases in China. Its clinical-stage product candidates include LZ901, a recombinant herpes zoster vaccine; K3, a recombinant human anti-TNF-a monoclonal antibody injection product for the treatment of various autoimmune diseases, such as rheumatoid arthritis, ankylosing spondylitis, and plaque psoriasis; and K193, a bispecific antibody injection to treat B cell leukemia and lymphoma. The company's pre-clinical-stage product candidates comprise Recombinant Varicella vaccine for the prevention of chickenpox caused by varicella-zoster virus; Recombinant Rabies vaccine to prevent rabies in humans; K333, a bispecific antibody injection product for the treatment of myeloid leukemia; and K1932 to treat B cell lymphoma. It also offers immunoreagent enzyme-linked kits, such as Group A meningococcal polysaccharide IgG, Group C meningococcal polysaccharide IgG, Group Y meningococcal polysaccharide IgG, Group W135 meningococcal polysaccharide IgG, and haemophilus influenzae Type b polysaccharide IgG antibody detection kits. The company also provides out-licensed products, including influenzae type b conjugate, Group ACYW135 meningococcal polysaccharide, Group A and C meningococcal - haemophilus influenzae type b conjugate, Group A and C meningococcal polysaccharide, and Group A and C meningococcal polysaccharide conjugate vaccine products. The company has a strategic cooperation with Tianjin Ringpu Bio-Technology Co., Ltd. to develop monoclonal antibody drugs and genetically engineered vaccines for pets. Beijing Luzhu Biotechnology Co., Ltd. was founded in 2001 and is headquartered in Beijing, China.